PharmAbcine expedites groundbreaking cancer treatment
This month, PharmAbcine executed its joint drug development with MDS, Merck’s international arm
[Country Business Reports interviews and articles by Discovery Reports www.discoveryreports.com]
PharmAbcine, a clinical stage immuno-oncology company developing next-generation antibody therapeutics for unmet medical needs, has established its anti-cancer drug candidate Tanibirumab (TTAC-0001) as one of the most promising in the global pipeline. To prolong the lives of terminally ill patients and raise their quality of life, the company is pursuing partnerships that would advance treatment for aggressive cancer conditions.
This month, the company executed its joint drug development with MDS, Merck’s international arm. They are testing the combination of Tanibirumab (TTAC-0001) and immunotherapy drug Keytruda.
“The response rate of approved immune checkpoint blockade drugs is still at a low 20 per cent. Since Tanibirumab (TTAC-0001) is safer and efficacious, its combination with Keytruda will be more synergistic for unmet medical needs such as brain tumours and triple-negative breast cancer,” says Dr Yoo Jin-san, president and CEO of PharmAbcine. “Tanibirumab (TTAC-0001) and Keytruda are able to pass the blood-brain barrier, so we hope to tackle many solid tumours that advance to brain metastasis with our combination trial.”
Meanwhile, a leading global biotechnology company headquartered in South Korea will collaborate with PharmAbcine for future medical needs. This partnership could bolster various natural killer (NK) cell therapy and chimeric antigen receptor T/NK therapy.
We keep track of critical developments because cancer also evolves
In order to address the rapidly growing prevalence of cancer in Asia, specifically in China and Southeast Asia, PharmAbcine licensed Tanibirumab (TTAC-0001) and PMC-001 (DIG-KT), its novel bi-specific antibody that stops tumour growth, to Shenyang-based 3SBio in 2014/2015. The collaboration could eventually address cancer in the stomach, lung, liver, pancreas, ovaries, brain and breasts.
